This portal should only be accessed by patients who have been prescribed this medicine by their Healthcare Professional.

These resources are only to be provided to patients who have already been prescribed Hemlibra^® (emicizumab) by their physician.

They need to be used along with the Patient Information Leaflets and additional Risk Minimisation Materials provided to you by your healthcare provider, namely ‘Hemlibra^® (emicizumab): Patient/Carer Guide‘  and ‘Hemlibra^® (emicizumab): Patient Alert Card’.

Our contact points: 

Pharmaceuticals
Roche Products (Ireland) Limited, 3004 Lake Drive, Citywest, Dublin 24, Ireland.
Telephone: +353 (0)1 469 0700

Your scientific questions about Roche products

Have a product information question? The Roche Medical Information department serves to communicate balanced information about our products.

Contact the Medical Information department:

Telephone: 01-4690700 
Email: [email protected]
Please note that Roche can not advise on medical treatments of individuals.

The attending physician is responsible for all decisions related to the prescribing of medication and medical treatment of the patient.

Contact the Pharmacovigilance department

Reporting side effects after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Please report any suspected adverse events (side effects) to: 

The Drug Surveillance Centre
Pharmacovigilance department 
Roche Products (Ireland) Limited
3004 Lake Drive, Citywest,
Naas Road, Dublin 24
Telephone: (01) 4690700
Email: [email protected]

Webform: https://medinfo.roche.com/ie/en.html

Alternatively, any suspected adverse reactions (side effects) can be reported to:

HPRA Pharmacovigilance
Website: www.hpra.ie

Diagnostics

Telephone: 1800 509 586 (freefone from Republic of Ireland)

Further contact details here